|
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
- Demonstrated brain imaging analysis solutions, including 'Neurophet AQUA AD,' which enables monitoring of adverse effects associated with Alzheimer's disease treatments
- Highlighted clinical cases that improved the safety of anti-amyloid therapy administration during an AI Theater session
SEOUL, South Korea, Dec. 5, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 5th that it participated in the 111th Radiological Society of North America (RSNA 2025) and presented real-world clinical use cases of its key brain imaging analysis AI solutions.
At the conference, Neurophet showcased its software 'Neurophet AQUA AD,' which supports monitoring of Alzheimer's disease treatment prescription, therapeutic response, and potential adverse effects. Neurophet AQUA AD provides precise brain imaging analysis throughout the administration of anti-amyloid antibody therapies by quantitatively analyzing magnetic resonance imaging (MRI) and positron emission tomography (PET) scans.
In addition, real-world clinical use cases of Neurophet AQUA AD were demonstrated during the AI Theater session held in the exhibition hall. In this session, Professor Chong Hyun Suh from the Department of Radiology at Asan Medical Center, University of Ulsan College of Medicine, delivered a lecture titled "AI-Powered Monitoring of Amyloid-Related Imaging Abnormalities in Anti-Amyloid Therapy: Neurophet AQUA AD."
Professor Suh introduced AI-based ARIA detection and quantification technologies that address the limitations of conventional manual approaches. He also elaborated how AI enhances the safety and clinical effectiveness of anti-amyloid therapies by presenting various real-world clinical cases in which patients receiving Alzheimer's disease treatments developed ARIA.
Through booth exhibition, Neurophet also presented Neurophet AQUA AD alongside its other solutions, including Neurophet AQUA, a brain neurodegeneration imaging analysis software, and Neurophet SCALE PET, a PET imaging quantification software.
The company highlighted the technological excellence of Neurophet AQUA MS, which was first unveiled at last year's RSNA. Neurophet AQUA MS is a software module integrated into Neurophet AQUA that analyzes brain images of patients with multiple sclerosis, a refractory central nervous system disorder. The solution received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in October of last year.
Jake Junkil Been, Co-CEO of Neurophet, stated, "Neurophet AQUA AD has been gaining significant attention from major domestic and global companies in the field of imaging analysis for Alzheimer's disease treatment planning. Through partnerships with global medical device companies at RSNA 2025, we plan to accelerate the expansion of our key products in the North American market."
Meanwhile, RSNA 2025 is the world's largest radiology conference, attended by radiologists and global medical device industry professionals, and is held annually in Chicago, USA. This year's conference took place from November 30 to December 4 (local time).
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurophet Participates RSNA 2025, Showcased Real-World Clinical Use Cases of 'Neurophet AQUA AD'
- Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies
- This partnership will generate revenue through:
- A computational longevity platform, including unique curated datasets and accelerated computation methods relevant for longevity research
- Next-generation drug candidates against sarcopenia
- Next generation drug candidates for dry age-related macular degeneration
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) and plans to expand the platform to other modalities. This strategic initiative, also supported by Singapore's Enterprise Singapore, is aligned with priority target areas in Singapore's Research, Innovation and Enterprise (RIE) 2030 plan.
LynxKite Technologies, a leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, will integrate AI computational methods relevant for longevity research into its computational orchestration platform. With over a decade of experience, the founding team of LynxKite has supported more than 100 global enterprises — including major players such as Roche, AstraZeneca and Hummingbird Biosciences — in analyzing complex data using graph-based and generative AI approaches.
The first MASSIVE project aims to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia, a degenerative muscle disease associated with aging that affects millions of elderly people worldwide. Biophytis contributes its deep expertise in age-related diseases, its preclinical experience in MasR-linked indications, and its expertise in Mas receptor pharmacology. LynxKite brings state-of-the-art AI technologies, chemoinformatics, and software engineering coupled with scaling GPU computation on the latest generation of NVIDIA toolkits and neoclouds such as Nebius. Together, the partners strengthen Biophytis' strategic drug discovery program, aligned with its longevity-focused strategy and positioning.
The project's key objectives include:
- Modeling the Mas receptor for structure-based drug design using AI and protein prediction tools.
- Designing and prioritizing synthetic drug candidates through AI-guided molecule generation and predictive filtering.
- Synthesizing and testing promising MasR activators to assess biological activity, safety, and pharmacokinetics.
- Selecting and protecting the lead candidate through patent filings in preparation for preclinical development.
- Developing and validating the AI software via feedback loops from in vitro and in vivo validation of candidates.
"The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia," said Stanislas Veillet, CEO of Biophytis.
Gyorgy Lajtai, CEO of LynxKite, added: "We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities."
About LynxKite
LynxKite Technologies Pte Ltd, headquartered in Singapore with offices in the United States, Switzerland The LynxKite platform combines graph analytics, biological language models, while directly managing, optimizing, and autoscaling GPU resources to efficiently run complex pipelines such as NVIDIA NIM Microservices. Building on more than a decade of experience in graph and enterprise AI, LynxKite collaborates with research institutions, technology partners, and industry leaders to accelerate scientific discovery and advanced analytics. For more information, please visit https://lynxkite.com.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
About Nebius
Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide. Nebius is listed on Nasdaq (NASDAQ: NBIS) and headquartered in Amsterdam. For more information, please visit www.nebius.com.
SINGAPORE, PARIS and CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Lynxkite is expanding its partnership with Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis"), starting with the MASSIVE project (MAS Receptor Synthetic Innovation & Virtual Engineering for Sarcopenia therapy) and plans to expand the platform to other modalities. This strategic initiative, also supported by Singapore's Enterprise Singapore, is aligned with priority target areas in Singapore's Research, Innovation and Enterprise (RIE) 2030 plan.
LynxKite Technologies, a leader in advanced analytics and artificial intelligence, known for its flagship open-source platform LynxKite, will integrate AI computational methods relevant for longevity research into its computational orchestration platform. With over a decade of experience, the founding team of LynxKite has supported more than 100 global enterprises — including major players such as Roche, AstraZeneca and Hummingbird Biosciences — in analyzing complex data using graph-based and generative AI approaches.
The first MASSIVE project aims to identify and develop Mas receptor (MasR) activator drug candidates targeting sarcopenia, a degenerative muscle disease associated with aging that affects millions of elderly people worldwide. Biophytis contributes its deep expertise in age-related diseases, its preclinical experience in MasR-linked indications, and its expertise in Mas receptor pharmacology. LynxKite brings state-of-the-art AI technologies, chemoinformatics, and software engineering coupled with scaling GPU computation on the latest generation of NVIDIA toolkits and neoclouds such as Nebius. Together, the partners strengthen Biophytis' strategic drug discovery program, aligned with its longevity-focused strategy and positioning.
The project's key objectives include:
"The launch of MASSIVE marks a decisive step in our longevity strategy, combining our clinical expertise with LynxKite's innovative AI to accelerate the discovery of transformative therapies against sarcopenia," said Stanislas Veillet, CEO of Biophytis.
Gyorgy Lajtai, CEO of LynxKite, added: "We are proud to collaborate with Biophytis on pioneering computational longevity through our LynxKite platfom, which demonstrates how LynxKite can revolutionize discovery by designing, integrating and orchestrating relevant computational tools in diverse modalities."
About LynxKite
LynxKite Technologies Pte Ltd, headquartered in Singapore with offices in the United States, Switzerland The LynxKite platform combines graph analytics, biological language models, while directly managing, optimizing, and autoscaling GPU resources to efficiently run complex pipelines such as NVIDIA NIM Microservices. Building on more than a decade of experience in graph and enterprise AI, LynxKite collaborates with research institutions, technology partners, and industry leaders to accelerate scientific discovery and advanced analytics. For more information, please visit https://lynxkite.com.
About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.
About Nebius
Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide. Nebius is listed on Nasdaq (NASDAQ: NBIS) and headquartered in Amsterdam. For more information, please visit www.nebius.com.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
